An Update on the Safety and Tolerability of Pimecrolimus Cream 1%: Evidence from Clinical Trials and Post-Marketing Surveillance

In this report, we review the data on the safety and tolerability of pimecrolimus cream 1% (Elidel®) from clinical trials and post-marketing surveillance in patients with atopic dermatitis. These data demonstrate that topically applied pimecrolimus is minimally absorbed through the skin and has afav...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Dermatology (Basel) 2007-01, Vol.215 (Suppl 1), p.27-44
Hauptverfasser:	Langley, Richard G.B., Luger, Thomas A., Cork, Michael J., Schneider, Dirk, Paul, Carle
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Cutaneous Animals Calcineurin Inhibitors Clinical Trials as Topic Dermatitis, Atopic - drug therapy Glucocorticoids - administration & dosage Glucocorticoids - adverse effects Herpes simplex virus Humans Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - adverse effects Immunosuppressive Agents - pharmacokinetics Neoplasms - chemically induced Product Surveillance, Postmarketing Skin Absorption Skin Diseases, Infectious - chemically induced Tacrolimus - administration & dosage Tacrolimus - adverse effects Tacrolimus - analogs & derivatives Tacrolimus - pharmacokinetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!